Princess Máxima Center participates in a consortium for more medicines
Recently the website from the European consortium ITCC-P4 that aims to get more medicines available for children with cancer went live. The Molenaar and Clevers groups of the Princess Máxima Center are participating in this consortium. Group Molenaar is involved in the identification of new targets and together with the Clevers group involved in the development of new model systems for solid tumors.
Cancer remains the leading cause of death in children and adolescents. Despite large claims, 6000 young people still die of cancer every year in Europe. In our country 25% of the approximately 600 children diagnosed with cancer every year do not survive the disease. There is therefore an urgent need to reduce delays in starting the development of oncological drugs and to better assess which drugs are effective in the treatment of cancer. ITCC-P4, which started earlier this year, is a platform to accelerate drug development for children and adolescents. The aim is to establish 400 new patient-derived prehospital models for the next five years, which can then be used for drug testing. The ultimate goal is to be able to further improve the treatment of young patients so that our mission "cure every child with cancer, with optimal quality of life", comes closer.
More information is available on the website www.itccp4.eu